Trial Information

SWOG S1106 Phase II Randomized Study of Induction Therapy Comprising Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Methotrexate, Cytarabine, and Leucovorin Calcium Versus Rituximab and Bendamustine Hydrochloride Followed by Consolidation Therapy and Autologous Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

This study is being done to find out what effects, good and/or bad, a combination of drugs called "R-HCVAD/MTX/ARA-C" vs. "R-bendamustine" followed by a stem cell transplant has on you and your mantle cell lymphoma. (7/12/12) The drugs in the R-HCVAD/MTX/ ARA-C combination are rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine. The drugs in R-bendamustine are rituximab and bendamustine. All of the drugs used in this protocol are FDA approved

Patient Inclusion Criteria:

All patients must have previously untreated stage III, IV, or bulky stage II mantle cell lymphoma (MCL)
Patients must not have clinical evidence of central nervous system (CNS) involvement by lymphoma
Any laboratory or radiographic tests performed prior to registration to assess CNS involvement must be negative
Patients must have a unilateral/bilateral bone marrow aspirate and biopsy for staging performed within 42 days prior to registration
If the biopsy cannot be performed but the aspirate is unequivocally consistent with mantle cell lymphoma, this will be considered adequate for staging purposes
Patients must be eligible for stem cell transplantation by institutional guidelines with the plan that transplant will be conducted at a cooperative group-approved transplant center
Patients must be planning to undergo stem cell transplantation within 84 days after day 1 of the last induction course

Patient Exclusion Criteria:

Zubrod performance status of 0-2
Bilirubin ≤ 3 times upper limit of normal (ULN)
Serum creatinine ≤ 2.0 times ULN
ALT and AST ≤ 2.5 times ULN
All patients ≥ 45 years of age must have an echocardiogram (ECHO) or MUGA scan within 42 days prior to registration (whichever method is used at baseline must be used at restaging)
Patients < 45 years of age should have ECHO/MUGA only if clinically indicated
Patients with an ejection fraction < institutional lower limit of normal (ILLN) are not eligible
Serum LDH and a CBC with differential must be measured within 28 days prior to registration
Patients known to be HIV positive, or who have a history of solid organ transplantation, are ineligible
No active hepatitis
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer; in situ cervical cancer; adequately treated Stage I or II cancer from which the patient is currently in complete remission; or any other cancer from which the patient has been disease-free for 5 years
Pregnant or nursing women may not participate
Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method

Janeen V. Bazan, RN OCN BSN CCRP, Oncology Research Nurse Program Coordinator
Sherman Health
1425 North Randall Road
Elgin, IL 60123
Phone: 224-783-2907
Fax: 224-783-3071
Email: janeen.bazan@shermanhospital.org

View Map

Research Center Information: Sherman Health

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:
Message:

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.